Diisopropylethylamine → HCID 24955701, 화합물

HRID 448041

반응식

HRID 448041 반응식
[S:1]1[CH:5]=[CH:4][N:3]=[C:2]1C(O)=O.CN([C:12]([O:16]N1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CCN(C(C)C)C(C)C.[I-].[CH2:43]([N+:47]1[N:51]=[C:50]([CH3:52])[S:49][C:48]=1[CH3:53])[CH2:44][CH2:45][CH3:46]>>[CH2:43]([N:47]1[N:51]=[C:50]([CH3:52])[S:49]/[C:48]/1=[CH:53]\[C:12]([C:4]1[N:3]=[CH:2][S:1][CH:5]=1)=[O:16])[CH2:44][CH2:45][CH3:46]

참가 물질

5

반응물 4

HCID 81531DiisopropylethylamineHCID 27627331,3-Thiazole-2-carboxylic acidHCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 691879173-Butyl-2,5-dimethyl-1,3,4-thiadiazol-3-ium iodide

생성물 1

HCID 24955701HCID 24955701, 화합물

실험 절차

In a 20 mL vial thiazole-2-carboxylic acid (0.9 mL of 0.2 M in DMA, 1.10 equiv) was added followed by the addition of HATU (77 mg in 0.7 mL of DMA, 0.2 mmol, 1.20 equiv.), DIEA (53 mg in 0.7 mL of DMA, 0.4 mmol, 2.40 equiv.), and finally 3-butyl-2,5-dimethyl-1,3,4-thiadiazol-3-ium iodide (50 mg in 0.7 mL of DMA, 0.17 mmol, 1 equiv.). The mixture was shaken overnight at room temperature and then concentrated in vacuo. The resulting residue was taken up in 1:1 DMSO/MeOH and purified by reverse phase HPLC using a method analogous to that described in Example 53 to provide the title compound. 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm 0.89 (t, 3 H) 1.25-1.38 (m, 2 H) 1.69-1.82 (m, 2 H) 2.46 (s, 3 H) 4.12-4.20 (m, 2 H) 6.81 (s, 1 H) 8.24 (s, 1 H) 9.15 (s, 1 H); MS (ESI) m/z 282 (M+H)+.

후처리

  1. concentrationconcentrated in vacuo
  2. custompurified by reverse phase HPLC

출처 및 근거

ORD 기록
ord-f5c76aa16f22436481cac3a2fa1d5e05
출처 데이터셋
uspto-grants-2013_07
특허 번호
US08481574B2

연결된 노트

불러오는 중…